A Double Blind, Randomised, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Intranasal Fluticasone Propionate Delivered by the Optinose Device in Adult Patients with Bilateral Nasal Polyposis
A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine.
A single centre, double blind, randomised, parallel group study to explore the efficacy and tolerability of intranasal fluticasone propionate compared with placebo delivered by the OptiNose device in adult subjects with chronic rhinosinusitis. - OptiNose Intranasal Fluticasone Propionate and Chronic Rhinosinusitis
100 Clinical Results associated with OptiNose UK Ltd.
0 Patents (Medical) associated with OptiNose UK Ltd.
100 Deals associated with OptiNose UK Ltd.
100 Translational Medicine associated with OptiNose UK Ltd.